Ask AI
2025 ASH Lymphomas

CE / CME

Key Studies in Lymphomas/CLL: Independent Conference Coverage of the 2025 ASH Annual Meeting

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 26, 2026

Expiration: August 25, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this text-based module, Jeremy S. Abramson, MD, MMSc, and Brad S. Kahl, MD, summarize and review the clinical implications of key studies in lymphomas and chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology (ASH) Annual Meeting. 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those who practice in academic or community settings, please indicate your practice setting:

How many people with lymphomas do you provide care for in a typical month?

A patient newly diagnosed with CLL requiring treatment arrives in your care. They have IGHV mutated, TP53 wild-type CLL, and no significant comorbidities. They are interested in time-limited therapy. Based on data presented at ASH 2025 from the phase III CLL17 trial, how would you counsel this patient regarding 3-year progression-free survival (PFS) rates with fixed-duration venetoclax plus obinutuzumab and ibrutinib plus venetoclax vs single-agent, continuous ibrutinib?

Which of the following was reported from the phase III BRUIN CLL-314 study of pirtobrutinib vs ibrutinib in patients with treatment-naive CLL or BTK inhibitor–naive relapsed/refractory (R/R) CLL?

In the phase I CaDAnCe-101 study evaluating BGB-16673 in heavily pretreated patients with R/R CLL/small lymphocytic lymphoma (SLL), which of the following patient populations showed response rates over 70%?

Surovatamig is a bispecific antibody (BsAb) that has shown very-high ORRs in a phase I trial that enrolled patients with previously treated follicular lymphoma (FL) and who were immunohistochemistry-positive for which of the following biomarkers?